Mustang Bio to Present at the Raymond James Human Health Innovation Conference

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia